PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1170396
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1170396
The Adenosine Receptors (A2a/A2b) Antagonists report covers the Adenosine Receptors (A2a/A2b) Antagonists market opportunity providing Key Competitive Analysis, 24+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. The report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area, and indication by phases. The Adenosine Receptors (A2a/A2b) Antagonists report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.
Adenosine is involved in a range of physiological and pathological effects through membrane-bound receptors linked to G proteins. There are four subtypes of adenosine receptors, described as A1AR, A2AAR, A2BAR, and A3AR, which are the center of cAMP signal pathway-based drug development. Several types of agonists, partial agonists or antagonists, and allosteric substances have been synthesized from these receptors as new therapeutic drug candidates. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions, and diabetes have been under development.
In this report, Mellalta Meets provides an in-depth analysis of Adenosine Receptors (A2a/A2b) Antagonists covering discovery, preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 27 candidate Adenosine Receptors (A2a/A2b) Antagonists products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Palobiofarma, Arcus Biosciences/Gilead Sciences, AstraZeneca/Sosei Heptares, Novartis/Palobiofarma, iTeos Therapeutics, Corvus Pharmaceuticals/Angel Pharmaceuticals.
As per analysis, A2AR/A2B Receptor inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME), and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing with the development pipeline full of molecules like small molecules, and combination therapies.